Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

In contemporary adjuvant therapy trials for early-stage breast cancer — which involved chemotherapy, endocrine therapy, or both — researchers have sought to identify and exploit small advantages of one therapy over another. Because breast cancer is so common, even modest improvements in therapy can translate into better outcomes for many patients. For the last decade, investigators have integrated taxanes into adjuvant chemotherapy regimens: Various taxanes, different schedules, and regimens in which taxanes were administered sequentially or concurrently with anthracyclines have been evaluated. The general consensus is that the integration of taxanes into adjuvant therapy regimens does improve clinical outcome incrementally, but many nuance…